Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OK, if one is inclined to rely on info released by the company (an iffy proposition) and
oh I care this pieceofcrap tapping the 0.3's again.
I hear Cramer is itching to break his SELLSELLSELL button on this.
WM, absolutely correct. Refills ... repeat patients on a life time drug. The kind of behavior that prompts physicians to add additional patients. Now if they only had a pill to discourage patients from tilting windbags ....
WM, absolutely correct. You know refills ... repeat patients on a life time drug. The kind of behavior that prompts physicians to find additional patients. Now if they only had a pill to discourage one from boxing shadows ....
maybe
Amen. Correct as usual Reverend. The land,building and monster scrap value must have some worth but $3M seems a push.
Holy Craypola!R.Heddle,4thCEO,baits snare to acquire JBI @$3M:
Sign me up for THAT deal!
He liked the company so much he bought it. For Three. Million. Dollars
It's only money. Novasep this early seems surprising. Was that on the chart?
0.85 ? why waste time with a 1for2 REV split ???
1 for 10 or 15 will make for more flashy killingzone finale
yup but the $3MILL was gone before the ink dried
getting their shares swindled makes normal people crazy. Like a Fox !
she twits and maybe tweets, holds last I read, but I imagine because she typically digs real and new news, not much to post over this long hot summer.
Boards aint the only place to be due to obvious strains from catdragged riffraff
Novasep NDA baby...Worlds Largest Chromatog. ~80% margins 2014.
BEDMINSTER, N.J. and DUBLIN, Ireland, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for Novasep Group, S.A.S., through its subsidiary Finorga S.A.S., as an additional Vascepa(R) (icosapent ethyl) active pharmaceutical ingredient (API) supplier. Novasep is part of the previously disclosed Slanmhor consortium with which Amarin announced a global supply agreement in 2012.
Novasep, a global leader in purification technologies and API manufacturing, is building the world's largest chromatography plant using its proprietary chromatography technologies to produce API on behalf of the Slanmhor consortium and Amarin. Amarin anticipates the Novasep facility, located in Mourenx, France, to be qualified and operational for manufacturing in 2014.
"This sNDA submission for Novasep brings to four the total number of suppliers that are approved or in regulatory review for Vascepa API production, including Nisshin Pharma, Inc. and following the recent FDA approvals of both BASF and Chemport as API suppliers for the product," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "The Novasep submission represents an additional step toward the goal of expanding our global supply chain to support expected Vascepa demand, diversify our supply base and ensure cost-efficient supply. As previously stated, the continued addition of these suppliers will potentially lead to API cost reductions of up to 50% or more and help us reach a steady state gross margin as a percentage of product revenues in the high seventies to low eighties."
This submission contributes to the planned expansion of the Vascepa manufacturing supply chain and is additional progress toward Amarin's goal to protect the commercial potential of Vascepa to beyond 2030 through a combination of patent protection, regulatory exclusivity, trade secrets and by taking advantage of manufacturing barriers to entry. Along with this planned expansion in supply, Amarin's significant progress includes expansion of patent protection for Vascepa in the United States with 27 Amarin patents either issued or allowed and over 30 additional patent applications being prosecuted in the United States. Amarin is also making significant progress with its patent applications related to Vascepa in multiple jurisdictions outside the United States, including the May 2013 patent grant by the European Patent Office covering the use of Vascepa based on the results from the MARINE trial.
Gevo hosts Biorefinery Ribbon Cutting/Plant-Tour Aug.26, Silsbee, TX.
http://www.thevindicator.com/news/article_20e3278a-0d44-11e3-8ac5-001a4bcf887a.html
Demonstration-scale plant will manufacture renewable paraxylene, a key future component of the Coca-Cola PlantBottle™, and alcohol-to-jet fuel for military applications
WHO:
- Patrick Gruber, CEO of Gevo
- Congressman Steve Stockman
- Jim Greenwood, CEO of the Biotechnology Industry Organization
WHAT: Gevo, Inc., the world’s only commercial producer of bio-based isobutanol, will host a ribbon cutting ceremony and plant tour for a demonstration-scale biorefinery. Isobutanol is an important platform chemical with broad applications in many chemicals and fuels markets, including paraxylene and alcohol-to-jet fuel.
• Gevo is working with Toray Industries, Inc., one of the world’s leading producers of fibers, plastics, and chemicals and The Coca-Cola Company to enable and deliver an integrated system to produce renewable paraxylene, a key future building block in reaching Coca-Cola’s vision of creating all of their packaging from renewable materials.
• To date, the United States Air Force has contracted Gevo to provide more than 50,000 gallons of its isobutanol-derived alcohol-to-jet (ATJ) fuel for testing by the Air Force Alternative Fuels Certification Division (AFCD). Gevo’s patented ATJ product is a drop-in fuel, deliberately designed to be fully compliant with aviation fuel specifications and provide equal performance, including fit-for-purpose properties.
WHEN: Mon., Aug. 26 at 11 a.m.
WHERE: 7752 FM 418
Silsbee, Texas 77656
"careful with your investment dollars. This Co has abysmal track record and abundant red flags" = evil conspirators
"all the SEC , legal and and financial woes are due to insane string of bogeymen" = cadre of Good.
Footprints pirouette across the ceiling.
Bullshit. TRx up. NRx up. RRx up. Schools in, people off the beach and settlin back into routine, payin dues for all those BBQs. Its almost hockey stick season, Lovaza is pucked.
Interview with Andrew Pearlman: (not new, short and oft misspelled ! )
President, Chief Executive Officer & Director
http://nbtequitiesresearch.com/sites/default/files/uploads/Medgenics_Inc_-_MDGN.pdf
Overlooked Splatacular raw data in Form 10-Q, the company reported $128,003 in total revenues, a 28.7% decrease from the second quarter of 2012. The company reported $69,903 in fuel revenues, a 29.5% decrease from the second quarter of 2012, and costs of goods sold related to fuel revenues of $113,046, a 42.4% increase from the second quarter of 2012. Net losses from continuing operations for the quarter were $2,555,716, compared to $4,028,390 in the second quarter of 2012.
The company produced 43,814 total gallons of fuel in the second quarter of 2013, compared to 68,569 gallons produced in the second quarter of 2012, a 36.1% decrease. Total cost per gallon was $2.43 per gallon, compared to $1.23 per gallon for the second quarter 2012, representing 98.2% increase in cost per gallon. We anticipate these figures to improve as many upgrades to our facility systems during the second quarter were required the shut down of all systems while construction was being completed. The primary focus of the company in the second quarter was to complete the assembly and start-up of our third processor.
correct as usual arvitar. Please include my name in your letter of high praise
Question-and-Answer Session. Operator;
Ladies and gentlemen, this concludes the second quarter 2013 results and operations update conference call.
source- transcript. LOL
Raw facts are JBII could quit cherry picking data points and mashing numbers together any time they wanted to. And any time it benefited them, they would. And any time they would NOT benefit, they won't. Its not that complicated
mañana banana
A major part is ALL about IP and exclusivity. There being NONE, in the minuscule chance this makes, instead of pisses off, any money, their edge is gone in 60 seconds flat. Cant AT ALL believe no other bright kid could not tweek the ebay-available-PID controlled processers, its simply NOT that complicated. The problem is keeping the machines running & stable & clean while repaying for the raw material costs all the way to the hopper. It was not only up time that killed the goose, it was $in vs.$out. Sorry, Game Over, Bye.
Wright Bros. Elon Musk. Einstein, who next? A luminary list compared to DJ (Defendant, John) Juicy grows more preposterous by the day. Take a hoohum cast off time debunked process, wrap some green tinsel around and promote the holy hell out of it ... and still there is only the money losing fraud besot fairytale story
thats odd then that somewhere between 20~50 THOUSAND entries in just alibaba seem to be waiting & hoping JBii will call with an order
Pyrolysis, Pyrolysis Products, Pyrolysis Suppliers and ... - Alibaba.com
www.alibaba.com/showroom/pyrolysis.html?
49758 Products - Pyrolysis, You Can Buy Various High Quality Pyrolysis Products from Global Pyrolysis Suppliers and Pyrolysis Manufacturers at Alibaba.com.
Pyrolysis Plant, Pyrolysis Plant Products, Pyrolysis ... - Alibaba.com
www.alibaba.com/showroom/pyrolysis-plant.html?
22870 Products - Pyrolysis Plant, You Can Buy Various High Quality Pyrolysis Plant Products from Global Pyrolysis Plant Suppliers and Pyrolysis Plant ...
you should always rely on your own DD if honestly interested in an business investment. I'd suggest as rank beginning some citations on a wiki article as one possibility to set up to speed, or just google oil recycling and come up with some of the Oil Bigs, they all have a plan. AFAIC, recycling oil is such a low margin, volume/know how/facility driven business (especially if piling on costs of RE-cracking & RE-catalyzing it to make ...wait here ... oil out of oil ) that its probably not worth expending the DD time past the easily uncovered candidates. Keep in mind that in addition to the tech & delivery track record, the integrity and stability of company lead figures, the reliability of their projections and their business dealings with others may make all fundamental DD worthless.
Hopefullly they'll get mercifully shagged in AC bad enough so not to be dragged in this slomo train wreck featuring;
1) Processors that have metatsized from simple, compact, cheap, even mobile, units, to building filling behemoths of unstable complexity.
2) Said processors that have yet to make one gallon of profitable fuel and now slide further behind the more technically adept and financially sound competitors with a spanky new expensive oil2oil scheme .
3) a parade of management figures that come and go, cheered then jeered, manage to get themselves barred for fraudulent actions, declare victory through every court ordered pay out, rise through the mucky ranks of MB trenches ... a real winners circle of hell
4) An untenable intellectual property position whose, if by some miracle ever did show a profit, advantage would evaporate in days.
Happy Gambling. Figure out who the rube at the table is before placing bets !
Writing bestseller, Need testimonials; "TradingJBII-RedMountainsGreenPebbles
Sofinnova MgmtVII/Dr James Healy files 6,321,588 ADRs
http://investor.amarincorp.com/sec.cfm
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. 6) 1
Amarin Corporation plc
(Name of Issuer)
Ordinary Shares, par value 50 pence per share
(Title of Class of Securities)
023111206
(CUSIP Number)
Nathalie Auber
Sofinnova Ventures, Inc.
2800 Sand Hill Road, Suite 150
Menlo Park, CA 94025
(650) 681-8420
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
COPY TO:
Linda Daley, Esq.
c/o Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
1200 Seaport Blvd., Redwood City, CA 94063
(650) 463-5243
April 3, 2012
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
This information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
__________________
1 On January 17, 2013, this Amendment No. 6 to Schedule 13D was filed under a prior CIK number of the Issuer, 1120246. The sole purpose of this filing is to re-file such Amendment under the current CIK number of the Issuer.
CUSIP NO. 023111206 13 D Page 2 of 10 Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Sofinnova Venture Partners VII, L.P. (“SVP VII”)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o (b) x
3
SEC USE ONLY
4
SOURCE OF FUNDS
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
6,321,588 American Depositary Shares (“ADSs”) (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants) except that Sofinnova Management VII, L.L.C. (“SM VII”), the general partner of SVP VII, may be deemed to have sole voting power, and Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”) and Eric P. Buatois (“Buatois”), the managing members of SM VII, may be deemed to have shared power to vote these ADSs.
8
SHARED VOTING POWER
See response to row 7.
9
SOLE DISPOSITIVE POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), except that SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power and Powell, Healy and Buatois, the managing members of SM VII, may be deemed to have shared power to dispose of these ADSs.
10
SHARED DISPOSITIVE POWER
See response to row 9.
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 6,321,588
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11
EXCLUDES CERTAIN SHARES
o
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6%
14 TYPE OF REPORTING PERSON PN
CUSIP NO. 023111206 13 D Page 3 of 10 Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Sofinnova Management VII, L.L.C. (“SM VII”)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o (b) x
3
SEC USE ONLY
4
SOURCE OF FUNDS
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are owned directly by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Powell, Healy and Buatois, the managing members of SM VII, may be deemed to have shared power to vote these ADSs.
8
SHARED VOTING POWER
See response to row 7.
9
SOLE DISPOSITIVE POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are owned directly by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Powell, Healy and Buatois, the managing members of SM VII, may be deemed to have shared dispositive power over these ADSs.
10
SHARED DISPOSITIVE POWER
See response to row 9.
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 6,321,588
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11
EXCLUDES CERTAIN SHARES
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6%
14 TYPE OF REPORTING PERSON OO
CUSIP NO. 023111206 13 D Page 4 of 10 Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Dr. Michael F. Powell (“Powell”)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o (b) x
3
SEC USE ONLY
4
SOURCE OF FUNDS
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Powell, a managing member of SM VII, may be deemed to have shared voting power to vote these ADSs.
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Powell, a managing member of SM VII, may be deemed to have shared power to dispose of these ADSs.
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 6,321,588
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11
EXCLUDES CERTAIN SHARES
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6%
14
TYPE OF REPORTING PERSON IN
CUSIP NO. 023111206 13 D Page 5 of 10 Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Dr. James I. Healy (“Healy”)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o (b) x
3 SEC USE ONLY
4
SOURCE OF FUNDS
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
60,000 ordinary shares.
8
SHARED VOTING POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Healy, a managing member of SM VII, may be deemed to have shared voting power to vote these ADSs.
9
SOLE DISPOSITIVE POWER
60,000 ordinary shares.
10
SHARED DISPOSITIVE POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Healy, a managing member of SM VII, may be deemed to have shared power to dispose of these ADSs.
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 6,381,588
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11
EXCLUDES CERTAIN SHARES
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.7%
14
TYPE OF REPORTING PERSON IN
CUSIP NO. 023111206 13 D Page 6 of 10 Pages
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Eric P. Buatois (“Buatois”)
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o (b) x
3
SEC USE ONLY
4
SOURCE OF FUNDS
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Permanent Resident
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
-0-
8
SHARED VOTING POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Buatois, a managing member of SM VII, may be deemed to have shared voting power to vote these ADSs.
9
SOLE DISPOSITIVE POWER
-0-
10
SHARED DISPOSITIVE POWER
6,321,588 ADSs (including 808,200 ordinary shares represented by ADSs subject to currently exercisable warrants), all of which are directly owned by SVP VII. SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Buatois, a managing member of SM VII, may be deemed to have shared power to dispose of these ADSs.
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON 6,321,588
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11
EXCLUDES CERTAIN SHARES
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11 4.6%
14 TYPE OF REPORTING PERSON IN
Statement on Schedule 13D
This Amendment No. 6 (“Amendment No. 6”) amends and supplements the statement on Schedule 13D initially filed on July 8, 2009 (as amended, the “Schedule 13D”) on behalf of Sofinnova Venture Partners VII, L.P., Sofinnova Management VII, L.L.C., Dr. Michael F. Powell, Dr. James I. Healy, and Eric P. Buatois (collectively, the “Sofinnova Reporting Persons”) and certain other reporting persons (collectively, the “Other Reporting Persons”) relating to the beneficial ownership of American Depositary Shares (“ADSs”) of ordinary shares, 50 pence par value per share (the “Ordinary Shares”) of Amarin Corporation plc (the “Issuer”). This Amendment No. 6 is being filed to reflect sales of ADSs and a warrant to purchase ADSs (“Warrant”) by the Sofinnova Reporting Persons. This Amendment No. 6 is being filed solely by the Sofinnova Reporting Persons. This Amendment No. 6 does not update any information relating to the Other Reporting Persons or the Other 2009 Investors (as defined in the Schedule 13D) except to the extent that the Sofinnova Reporting Persons are aware of changes in ownership by such other persons as the result of Section 13 filings with the Securities and Exchange Commission. Except as set forth below, this Amendment No. 6 does not supplement, restate or amend any of the other information disclosed in the Schedule 13D. Capitalized terms not defined in this Amendment No. 6 have the meanings ascribed to them in the Schedule 13D.
ITEM 4. Purpose of Transaction.
The Sofinnova Reporting Persons sold the securities of the Issuer as reported in this Amendment No. 6 for investment purposes.
ITEM 5. Interest in Securities of the Issuer.
Item 5(a) of the Schedule 13D is amended to amend and restate the references to Rows 7-11 and 13 of the cover page for the Sofinnova Reporting Persons as follows:
See Rows 7-11 and 13 of the cover page filed with this Amendment No. 6 for each Sofinnova Reporting Person. The percentage listed in Row 13 for each Sofinnova Reporting Person was calculated based upon 136,867,895 Ordinary Shares outstanding (includes 136,059,695 Ordinary Shares as of February 23, 2012, as reported by the Issuer and 808,200 Ordinary Shares represented by ADSs subject to currently exercisable warrants held by Sofinnova Reporting Persons).
Item 5(a) of the Schedule 13D is further amended to add the following information:
Based solely on a review of Section 13 filings made since February 1, 2012, the Sofinnova Reporting Persons are not aware of any changes in ownership by Other Reporting Persons. As a result of the sale of the ADSs and Warrant by the Sofinnova Reporting Persons reported in this Amendment No. 6, the Sofinnova Reporting Persons believe that together the Sofinnova Reporting Persons and the Other Reporting Persons may be deemed to beneficially own in the aggregate 18,881,379 ADSs (which includes 5,058,200 Ordinary Shares represented by ADSs issuable pursuant to currently exercisable warrants held by the Sofinnova Reporting Persons and Other Reporting Person), which represents 13.4% of Ordinary Shares outstanding of the Issuer (based on 141,117,895 Ordinary Shares outstanding, which includes 136,059,695 Ordinary Shares as of February 23, 2012, as reported by the Issuer and 5,058,200 Ordinary Shares represented by ADSs issuable pursuant to currently exercisable warrants held by the Sofinnova Reporting Persons and Other Reporting Persons).
Based solely on a review of Section 13 filings made since February 1, 2012, the Sofinnova Reporting Persons are not aware of any changes in ownership by Other 2009 Investors. As a result of the sale of the ADSs and Warrant by the Sofinnova Reporting Persons reported in this Amendment No. 6, the Sofinnova Reporting Persons believe that together the Sofinnova Reporting Persons, the Other Reporting Persons and the Other 2009 Investors (together the “Investors”) who are parties to a Securities Purchase Agreement, dated October 12, 2009, and that certain Management Rights Deed of Agreement entered into in connection therewith, may be deemed to beneficially own in the aggregate 43,130,282 ADSs (which includes 5,058,200 Ordinary Shares represented by ADSs issuable pursuant to currently exercisable warrants held by Investors), which represents 30.6% of Ordinary Shares outstanding of the Issuer (based on 141,117,895 Ordinary Shares outstanding, which includes 136,059,695 Ordinary Shares as of February 23, 2012, as reported by the Issuer and 5,058,200 Ordinary Shares represented by ADSs issuable pursuant to currently exercisable warrants held by Investors).
7
Item 5(b) of the Schedule 13D is amended to add the following information regarding the Sofinnova Reporting Persons: Other than the following open market sales of ADSs and the sale of a Warrant pursuant to the Warrant Purchase Agreement with OTA LLC dated April 3, 2012, the Sofinnova Reporting Persons have not engaged in any transactions in ADSs, Warrants, or Ordinary Shares in the past 60 days.
Date Number of ADSs Sold
Average Price
per ADS
03/28/2012 6,302 $ 11.73
03/29/2012 993,698 $ 10.98
04/02/2012 264,350 $ 10.9903
04/03/2012 1,735,650 $ 10.9813
Date Number of ADSs Subject to Warrant Sold Aggregate Price
04/04/2012 941,800 $ 8,506,337.60
Item 5(e) of the Schedule 13D is amended to add the following information regarding the Sofinnova Reporting Persons: In connection with the transactions reported hereunder, the Sofinnova Reporting Persons shall cease to be joint filers reporting beneficial ownership of more than five percent of a class of securities of the Issuer.
Item 6 of the Schedule 13D is amended to add the following information regarding the Sofinnova Reporting Persons:
See Item 5 regarding the Warrant Purchase Agreement with OTA LLC dated April 3, 2012.
Item 7 of the Schedule 13D is amended to add the following Exhibits:
Exhibit I Warrant Purchase Agreement with OTA LLC dated April 3, 2012
8
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: April 9, 2012
SOFINNOVA VENTURE PARTNERS VII, L.P., a Delaware Limited Partnership
By: SOFINNOVA MANAGEMENT VII, L.L.C., a Delaware Limited Liability Company
Its General Partner
By: /s/ Nathalie Auber
Nathalie Auber
Attorney-in-Fact
SOFINNOVA MANAGEMENT VII, L.L.C., a Delaware Limited Liability Company
By: /s/ Nathalie Auber
Nathalie Auber
Attorney-in-Fact
DR. JAMES I. HEALY
DR. MICHAEL F. POWELL
ERIC P. BUATOIS
By: /s/ Nathalie Auber
Nathalie Auber
Attorney-in-Fact
*Signed pursuant to a Power of Attorney already on file with the appropriate agencies.
9
EXHIBIT INDEX
Exhibit Description
I Warrant Purchase Agreement with OTA LLC dated April 3, 2012.
10
EXHIBIT I
WARRANT PURCHASE AGREEMENT
This Warrant Purchase Agreement (the “ Agreement ”), dated as of April 3, 2012, is by and between Sofinnova Venture Partners VII, L.P. (the “ Seller ”) and OTA LLC (the “ Buyer ”).
WITNESSETH :
WHEREAS , the Seller owns certain warrants issued on December 14, 2010 (collectively “the Warrant ”) to purchase up to an aggregate of 1,750,000 ordinary shares of Amarin Corporation PLC (the “ Issuer ”) common stock, having an exercise price equal to the greater of (i) US$1.50 per share of common stock or (ii) an amount in U.S. dollars equal to £0.50 per share of common stock (in each case, as adjusted for stock splits, stock dividends, stock combinations and the like), and an expiration date of October 16, 2014;
WHEREAS , the Ordinary Shares issuable upon exercise of the Warrant (the “ Warrant Shares ”) are currently registered pursuant to Registration Number 333-163704, which registration statement has been declared effective in accordance with the Securities Act of 1933, as amended (the “ Securities Act ”) by the United States Securities and Exchange Commission;
WHEREAS , the parties hereto desire that the Seller sells, transfers, conveys and assigns to Buyer, and Buyer purchases and acquires from the Seller, the Warrant (or a portion thereof) and any and all rights and benefits incident to the ownership thereof (including, without limitation, any registration rights pertaining to the portion of the Warrant sold);
NOW, THEREFORE , in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1. Sale and Purchase of Warrant; Settlement .
1.1 Sale and Purchase .
(a) Subject to the terms and conditions of this Agreement, on the Closing date of this Agreement, the Seller shall sell, convey, assign and deliver to Buyer, and Buyer shall purchase from the Seller, the Warrant (or the portion of the Warrant determined in accordance with Section 1.1(b) below) and any and all rights and benefits incident to the ownership thereof (including, without limitation, any registration rights pertaining to the portion of the Warrant sold).
(b) The parties agree that, for each Warrant Share that Buyer is able to sell under the instructions contained in this subparagraph, the Seller will sell to Buyer and Buyer will purchase one Warrant Share for the Purchase Price (defined below). Buyer agrees to purchase each Warrant Share for a purchase price equal to $9.90 (as adjusted, the “ Purchase Price ”), subject to adjustment as provided herein should the Buyer be unable to sell the Warrant Shares at a per share reference price of $11.50 within two (2) trading days. If Buyer is unable to sell all Warrant Shares within such two trading-day period, then Buyer shall seek written approval of the Seller prior to selling the remainder of such Warrant Shares (the “ Remaining Warrant Shares ”). Should Seller elect not to provide such approval, this Agreement shall terminate with respect to the sale of such Remaining Warrant Shares by Buyer on behalf of Seller (and the corresponding sale of the Warrant for such Remaining Warrant Shares from Buyer to Seller) hereunder and Seller shall sell and Buyer shall purchase only that portion of the Warrant that does not relate to the Remaining Warrant Shares. The Purchase Price of each Warrant Share will be adjusted to reflect the average price of all sales made by the Buyer pursuant to the Seller’s instructions hereunder for the Issuer’s common stock (NASDAQ: AMRN) multiplied by one-hundred percent (100%) (the “ Final Average ”). To clarify, the Seller will instruct the Buyer to sell a maximum of 1,750,000 shares of AMRN with a low-limit, which Seller may communicate to Buyer via electronic mail. The Purchase Price will be adjusted based on the Final Average of the stock sales. By way of example only, if all 1,750,000 shares of AMRN are sold by Buyer for a Final Average of $10.50 per share, the Purchase Price hereunder will be reduced by $1.00 to $8.90. The Buyer will furnish Seller with partial reports of common stock sales every hour the order is in effect and, based upon the foregoing, the Seller may adjust the low-limit.
1
(c) Within two (2) Business Days after the date hereof the Seller shall deliver or cause to be delivered to the Issuer the Warrant (to the extent the Issuer does not already hold such Warrant) together with a duly executed Form of Assignment with a request that the Issuer transfer the Warrant to, and issue and deliver the new warrant to the Buyer. Buyer will communicate directly with the Issuer in order to effect exercise of the Warrant pursuant to its terms.
(d) Upon receipt of notice from the Issuer of the Issuer’s re-issuance of the Warrant into the Buyer’s name, the Buyer shall wire transfer the Purchase Price to the Seller’s account. No transfer of the Warrant shall take place until the receipt of the Purchase Price by Seller (such time, the “ Closing ”).
1.2 Other Agreements . Buyer and Seller each represent and warrant that they have reviewed the purchase agreement (and registration rights agreement, if any) relating to the initial sale of the Warrant by the Issuer. Buyer and Seller each acknowledge that the sale and purchase made hereunder is expressly subject to the terms and conditions of such agreements. In addition, Buyer hereby expressly agrees to be bound by the terms and conditions thereof.
SECTION 2. Representations and Warranties of Buyer . Buyer represents and warrants to the Seller, as of the date hereof and as of the Closing, as follows:
2.1 Organization; Authority . Buyer is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate, partnership or other applicable power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder, and the execution, delivery and performance by the Buyer of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of the Buyer. This Agreement, when executed and delivered by the Buyer, will constitute a valid and legally binding obligation of the Buyer, enforceable against Buyer in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (c) to the extent the indemnification provisions contained herein may be limited by federal or state securities laws.
2.2 No Conflicts; Advice . Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated thereby, does or will violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge or other restriction of any government, governmental agency, or court to which the Buyer is subject or any provision of its organizational documents or other similar governing instruments, or conflict with, violate or constitute a default under any agreement, credit facility, debt or other instrument or understanding to which the Buyer is a party. Buyer has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Warrant.
2.3 No Litigation . There is no action, suit, proceeding, judgment, claim or investigation pending, or to the knowledge of the Buyer, threatened against the Buyer which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.
2.4 Buyer Status . At the time the Buyer was offered the Warrant, it was, at the date hereof it is, and on the Closing it will be, an “ accredited investor ” as defined in Rule 501(a) under the Securities Act and a “ qualified institutional buyer ” as defined in Rule 144(A) under the Securities Act, having such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Warrant and any Warrant Shares issued upon the exercise of the Warrant. Buyer was not solicited to purchase the Warrant through any form of general solicitation or general advertisement.
2
2.5 Consents . No authorization, consent, approval or other order of, or declaration to or filing with, any governmental agency or body or other person is required for the valid authorization, execution, delivery and performance by the Buyer of this Agreement and the consummation of the transactions contemplated hereby.
2.6 Sophistication . Buyer (i) is a sophisticated entity with respect to the purchase of the Warrant and underlying Warrant Shares, (ii) is able to bear the economic risk associated with the purchase of the Warrant, (iii) has such knowledge and experience so as to be aware of the risks and uncertainties inherent in the purchase of investments of the type contemplated in this Agreement, and (iv) has independently and without reliance upon Seller, and based on such information as Buyer has deemed appropriate, made its own analysis and decision to enter into this Agreement, except that Buyer has relied upon Seller's express representations and warranties in this Agreement. Buyer acknowledges that Seller has not given Buyer any investment advice, credit information or opinion on whether the purchase of the Warrant is prudent.
2.7 Non-Public Information . Buyer is not purchasing the Warrant “on the basis of” (as defined in Rule 10b5-1 of Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)) any material, non-public information about the Warrant or the Issuer.
SECTION 3. Representations and Warranties of the Seller . Seller represents and warrants to Buyer, as of the date hereof and as of the Closing, as follows:
3.1 Authorization of Agreement . Seller is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization with full right, corporate, partnership or other applicable power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder, and the execution, delivery and performance by the Seller of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of such Seller. This Agreement, when executed and delivered by the Seller, will constitute a valid and legally binding obligation of the Seller, enforceable against Seller in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (c) to the extent the indemnification provisions contained herein may be limited by federal or state securities laws.
3.2 Title to the Warrant . Seller is the lawful owner of the Warrant with good and marketable title thereto, and the Seller has the absolute right to sell, assign, convey, transfer and deliver the Warrant and any and all rights and benefits incident to the ownership thereof (including, without limitation, any registration rights pertaining to the Warrant), all of which rights and benefits are transferable by the Seller to Buyer pursuant to this Agreement, free and clear of all the following (collectively called “ Claims ”) of any nature whatsoever: security interests, liens, pledges, claims (pending or threatened), charges, escrows, encumbrances, lock-up arrangements, options, rights of first offer or refusal, community property rights, mortgages, indentures, security agreements or other agreements, arrangements, contracts, commitments, understandings or obligations, whether written or oral and whether or not relating in any way to credit or the borrowing of money. Delivery to Buyer of the Warrant will (i) pass good and marketable title to the Warrant to Buyer, free and clear of all Claims (assuming that the Buyer is a bona fide purchaser within the meaning of Section 8-302 of the New York Uniform Commercial Code), and (ii) convey, free and clear of all Claims, any and all rights and benefits incident to the ownership of such Warrant (including, without limitation, any registration rights pertaining to the Warrant).
3.3 No Conflicts; Advice . Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated thereby, does or will violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge or other restriction of any government, governmental agency, or court which the Seller is subject to and aware of, or any provision of its organizational documents or other similar governing instruments, or conflict with, violate or constitute a default under any agreement, credit facility, debt or other instrument or understanding to which the Seller is a party. Seller has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with its sale of the Warrant.
3
3.4 No Litigation . There is no action, suit, proceeding, judgment, claim or investigation pending, or to the knowledge of the Seller, threatened against the Seller which could reasonably be expected in any manner to challenge or seek to prevent, enjoin, alter or materially delay any of the transactions contemplated by this Agreement.
3.5 Consents . No authorization, consent, approval or other order of, or declaration to or filing with, any governmental agency or body or other person is required for the valid authorization, execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated thereby.
3.6 Bankruptcy . Seller is not under the jurisdiction of a court in a Title 11 or similar case (within the meaning of United States Bankruptcy Code Section 368(a)(3)(A) (or related provisions)) or involved in any insolvency proceeding or reorganization.
3.7 Non-Public Information . Seller is not selling the Warrant “on the basis of” (as defined in Rule 10b5-1 of the Exchange Act) any material, non-public information about the Warrant or the Issuer.
SECTION 4. Survival of Representations and Warranties; Etc . All representations and warranties of Buyer and the Seller shall survive the Closing for a period of one year. Seller may rely upon this Agreement for the purpose of assuring its compliance with applicable law.
SECTION 5. Indemnification .
Each party hereto shall indemnify, defend and hold harmless, the other party (and its respective affiliates, directors, officers, employees, successors and assigns) from and against any and all losses, claims, damages, liabilities and expenses based upon, arising out of or otherwise in respect of, any inaccuracy in, or any breach of, the representations or warranties of such party and the covenants or agreements made by such party in this Agreement.
SECTION 6. Notices . Any notice required or permitted by this Agreement shall be in writing and shall be deemed sufficient upon delivery, when delivered personally or by overnight courier or sent by fax (upon confirmation of receipt), or 72 hours after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, addressed to the party to be notified at such party’s address as set forth below.
Buyer
OTA LLC
One Manhattanville Road
Purchase, NY 10577
Attn: Stephan Skinner
Seller
Sofinnova Venture Partners VII, L.P.
2800 Sand Hill Road, Suite 150
Menlo Park, CA 94025
Attn: Nathalie Auber
SECTION 7. Successors and Assigns . This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective successors, heirs, personal representatives, and permitted assigns..
SECTION 8. Counterparts . This Agreement may be executed via facsimile in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
4
SECTION 9. Severability . If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
SECTION 10. Entire Agreement . This Agreement represents the entire agreement of the parties hereto and thereto with respect to the matters contemplated hereby and thereby, and there are no written or oral representations, warranties, understandings or agreements with respect thereto except as expressly set forth herein and therein.
SECTION 11. Amendments; Waivers . No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by each party or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought.
SECTION 12. Confidentiality . Each of the Buyer and the Seller hereby agrees, without the prior written consent of the other, to not disclose, and to otherwise keep confidential, the sale of the Warrant contemplated hereby, except to the Issuer and to the extent that disclosure thereof is required by law, rule or regulation; provided, however, that the Buyer and the Seller may disclose information regarding such sale to their respective accountants, attorneys, limited partners, shareholders and other interest holders.
SECTION 13. Further Assurances . Each of the Buyer and the Seller hereby agrees and provides further assurances that it will, in the future, execute and deliver any and all further agreements, certificates, instruments and documents and do and perform or cause to be done and performed, all acts and things as may be necessary or appropriate to carry out the intent and accomplish the purpose of this Agreement.
SECTION 14. Governing Law . This Agreement shall be governed by and construed in accordance with the internal laws of the State of California without regard to the conflicts of laws principles thereof.
SECTION 15. Dispute Resolution .
(a) All disputes or claims arising under or in any way relating to this Agreement shall be settled by arbitration before a panel of three arbitrators (with one designated by the Buyer and one designated by the Seller, and the third arbitrator designated by the first two) pursuant to the rules of the American Arbitration Association. Any arbitrator designated by the Buyer or the Seller must be an “ Independent Person .” For the purposes of this Section 15, an “ Independent Person ” shall be an individual who is not and has not been (i) a director, officer, employee, agent or shareholder of either party hereto, (ii) a consultant to either party hereto, (iii) a person with a direct or indirect financial interest in any contract with either party hereto, (iv) a director, officer or key employee of a company at a time when such company was party to a contract with either party hereto, or (v) a relative of any person referred to in clauses (i), (ii), (iii) or (iv) above. As used in the immediately preceding sentence, the term “ either party hereto ” shall be deemed to include any affiliates of the parties hereto. Any such arbitration shall take place in San Francisco, California. Arbitration may be commenced at any time by either party hereto giving written notice to the other party hereto that such dispute has been referred to arbitration under this Section 15. The third arbitrator shall be selected as prescribed above, but if the first two arbitrators do not so agree within 30 days after the date of the notice referred to above, the selection shall be made pursuant to the rules of the American Arbitration Association from the Commercial Arbitration Panel maintained by such Association. Any award rendered by the arbitrators shall be conclusive and binding upon the parties hereto; provided , however , that any such award shall be accompanied by a written opinion of the arbitrators giving the reasons for the award. In making such award, the arbitrators shall be authorized to award interest on any amount awarded. This provision for arbitration shall be specifically enforceable by the Seller and the Buyer and the decision of the arbitrators in accordance herewith shall be final and binding and there shall be no right of appeal therefrom. Each of the Seller and the Buyer shall pay its own expenses of arbitration and the expenses of the arbitrators shall be equally shared; provided , however , that if in the opinion of the arbitrators any claim or any defense or objection thereto was frivolous or in bad faith, the arbitrators may assess, as part of the award, all or any part of the arbitration expenses of the other party (including reasonable attorneys’ fees) and of the arbitrators against the party raising such unreasonable claim, defense or objection.
5
(b) The parties hereto acknowledge that a breach of this Section 15 would result in irreparable injury to the non-breaching party, and the non-breaching party will be entitled to seek equitable relief, including specific performance, to enforce the provisions of this Section 15.
[ Remainder of page intentionally left blank ]
6
IN WITNESS WHEREOF , the parties hereto have duly executed this Agreement as of the date first above-written.
OTA LLC
By:__________________________
Name: Ira Leventhal
Title: CEO
Sofinnova Venture Partners VII, L.P.
By: Sofinnova Management VII, L.L.C.
its General Partner
By:_______________________________ Managing Member
7
whos your uncle, lil nce ?
Patent Data
Appl No Prod No Patent No Patent
Expiration Drug Substance
Claim Drug Product
Claim Patent Use
Code Delist
Requested
N202057 001 8188146 Jan 27, 2020 Y Y
N202057 001 8293727 Feb 9, 2030 U - 1287
N202057 001 8293728 Feb 9, 2030 U - 1287
N202057 001 8298554 Apr 29, 2030 Y
N202057 001 8314086 Feb 9, 2030 U - 1287
N202057 001 8318715 Feb 9, 2030 U - 1287
N202057 001 8357677 Feb 9, 2030 U - 1287
N202057 001 8367652 Feb 9, 2030 U - 1287
N202057 001 8377920 Feb 9, 2030 U - 1287
N202057 001 8399446 Feb 9, 2030 U - 1287
N202057 001 8415335 Feb 9, 2030 U - 1287
N202057 001 8426399 Feb 9, 2030 U - 1287
N202057 001 8431560 Feb 9, 2030 U - 1287
N202057 001 8440650 Feb 9, 2030 U - 1287
N202057 001 8445003 Apr 29, 2030 U - 1287
N202057 001 8445013 Apr 29, 2030 U - 1287
N202057 001 8501225 Apr 29, 2030 U - 1287
27,000 impatient invfestors just banged the exit gate to oh4oh.
I'll never understand that now that things are all better with prop letters to prove it , down at the House of JBI ..
damn I type sloe. THIRTY NINE THOUSAND
Thanks; honesty around here is a rare breeze.
Because realistically; just how many companies have a reliable high volume source of consistent ideal plastic feed stock ?
And how many of those do you suppose want to shift from a brute operation of compactor / baler / forklift, to submerge into the uncharted maintenance quicksand diversions of the 3-headed building-sized monster JBI has arrived at ? Its like starting a new division just for a couple tanks of naptha & diesel ! They could probably drill their parking lots for that much oil.
My humble opinion is that once this process outgrew the single, compact reactor concept it was doomed, all over except for milking sub-informed investors via a cynical orchestrated smoke & mirror show.
I picture an operation on the size of a steel mill or float glass plant ( not that they have plastic, but that scale of operation) even passably interested in doing something other than calling in the truckers to cart the bales off.
And those guys would look at all the problems running an unstable refinery-like process then decide to simply incinerate the waste for direct heating. Pretending a properly run incinerator in any less "green" than than these whack engineered fuel converters is positively ludicrous.
No way on God's green thermodynamically constrained earth can you add an entire heat process step on plastic, to make oil, more efficiently than you can simply burn it under a boiler. By this I refer to the heat radiating off The Monster, or going up it's stack as a lost opportunity, which is not paid back by the conversion to liquid fuel. Its just one more wasted step in the final goal of oxidizing all those hydrocarbons.
What about "passing the technology on" ?? Consider the appalling lack of any genuine IP on the MagiCatalyst (which, recall, was originally touted as The Philosopher's Stone making JBIs process an iota different from any of the other hundreds of attempts at pyro), thus the requirement we all suspend healthy critical thought and take the word of a rather strange duck guy who (to put it mildly) frankly & provably & repeatedly has not cultivated his credibility to justify anything like that kind of faith.
So at best a "machine sales" path is looking at a humble middleman turn key vendor between some fab shop in China and one of the few industries scaled to take on the challenges.
The more realistic alternative is a central & independent processor of several streams of waste plastic, but, given the formidable complexity & logistic hurdles of those waste streams, we see the effect in each partially decipherable info leak from JBII - the feedstock cost:benefit relationship lies somewhere red of profitability.
So I wish you incredible good luck in your investment, as I think that's the only hope at this point.
WmJ; a prescient sayed is a penny earned ...
I have not done digging but the OP / other board is getting some corrections -
seems more like the recently rejected epanova-like pats by AMRN are behind his claim.
Trading Halt Lifted. Not that JBI notices - more more of the same same.
Trade volumes show lofty red towers corn studded with random green pebbles.